|
시장보고서
상품코드
2008818
바이러스 불활성화 시장 보고서 : 제품별, 용도별, 최종 용도별, 지역별(2026-2034년)Viral Inactivation Market Report by Product, Application, End Use, and Region 2026-2034 |
||||||
세계의 바이러스 불활성화 시장 규모는 2025년에 7억 4,960만 달러에 달했습니다. 향후에 대해 IMARC Group은 2034년까지 시장 규모가 14억 9,320만 달러에 달하며, 2026-2034년에 CAGR 7.96%로 성장할 것으로 예측하고 있습니다.
생물제제에는 바이러스가 포함되어 있거나 제조 과정에서 오염될 수 있습니다. 바이러스는 세포에 침입하여 증식하여 각종 질병을 유발하는 감염성 입자입니다. 그 결과, 바이러스의 외투 단백질을 억제하고 바이러스내 핵산을 분해하기 위해 바이러스 불활성화가 널리 이용되고 있습니다. 현재 전 세계에서 바이러스의 특성이나 바이오 치료제의 유형에 따라 다양한 바이러스 불활성화 방법이 활용되고 있습니다. 예를 들어 살균용(UVC) 광선 조사는 병원 및 기타 중요한 공공 및 군사 환경에서 바이러스를 비활성화하는 데 도움이 됩니다.
바이러스 비활성화 시장 동향:
인간의 혈액은 생명을 위협하는 질병의 예방과 치료에 도움이 되는 의약품의 원료입니다. 혈장 유래 의약품을 통한 혈액 매개 바이러스 전파에 대한 우려가 높아지면서 전 세계에서 바이러스 불활화의 필요성이 대두되고 있습니다. 현재 혈장 유래 단백질 제제의 안전성을 보장하기 위해 여러 가지 바이러스 비활성화 공정이 채택되고 있습니다. 또한 많은 국가의 규제 당국은 바이오의약품 개발 초기 단계에서 엄격한 규제 기준을 도입하고 있습니다. 이러한 기준은 제품의 품질, 안전성, 유효성을 보장하고 교차 오염의 위험을 줄이기 위해 바이러스 비활성화에 대한 수요를 높이고 있습니다. 이와는 별도로 식품 및 음료(F&B) 업계에서도 장내 바이러스 전파를 억제하고 제품의 안전성을 보장하기 위해 개선된 바이러스 불활성화 기술 및 제품을 채택하고 있습니다. 이는 초임계 유체, 가스 플라즈마, 펄스 전기장과 같은 새로운 물리적 기법의 개발과 함께 바이러스 불활화의 신뢰성, 편의성 및 적응성을 향상시켜 시장 성장을 촉진할 것으로 예상됩니다.
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 개요
제4장 서론
제5장 세계의 바이러스 불활성화 시장
제6장 시장 내역 : 제품별
제7장 시장 내역 : 용도별
제8장 시장 내역 : 최종 사용별
제9장 시장 내역 : 지역별
제10장 SWOT 분석
제11장 밸류체인 분석
제12장 Porter's Five Forces 분석
제13장 가격 분석
제14장 경쟁 구도
KSA 26.04.30The global viral inactivation market size reached USD 749.6 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 1,493.2 Million by 2034, exhibiting a growth rate (CAGR) of 7.96% during 2026-2034.
Biotherapeutic products contain viruses or they can become contaminated during the production process. Viruses are infectious particles that invade cells wherein they proliferate and result in various diseases. As a result, viral inactivation is widely used to inhibit coat proteins and degrade nucleic acid within the virus. At present, different methods of viral inactivation are available across the globe according to the characteristics of the virus and the type of biotherapeutic product. For instance, germicidal (UVC) light exposure helps inactivate viruses in hospitals and other critical public and military environments.
VIRAL INACTIVATION MARKET TRENDS:
Human blood is a source of medicinal products that assists in the prevention and treatment of life-threatening diseases. Rising concerns about the transmission of blood-borne viruses through plasma-derived medicinal products represent one of the significant factors influencing the need for viral inactivation around the world. Several procedures for viral inactivation are nowadays used to assure the safety of blood plasma-derived protein solutions. Moreover, governing agencies of numerous countries are introducing stringent regulatory standards at an early stage in the development of biotherapeutic products. These standards are escalating the demand for viral inactivation to ensure the quality, safety, and efficacy of these products, thereby reducing the risk of cross-contamination. Apart from this, improved viral inactivation technologies and products are being employed in the food and beverage (F&B) industry to help control the transmission of enteric viruses and assure the safety of products. This, in confluence with the development of new physical methods like supercritical fluids, gas plasma, and pulsed electric fields, is anticipated to increase the reliability, convenience, and suitability of viral inactivation, thereby driving the market.
KEY MARKET SEGMENTATION:
Breakup by Product:
- Reagents and Kits
- Systems
- Services
Breakup by Application:
- Vaccines and Therapeutics
- Stem Cell Products
- Blood and Blood Products
- Tissue and Tissue Products
- Cellular and Gene Therapy
Breakup by End Use:
- Pharmaceutical and Biotechnology Companies
- CROs
- Academic and Research Institutes
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
COMPETITIVE LANDSCAPE:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Charles River Laboratories, Merck KGaA, Parker Hannifin Corp, Rad Source Technologies, Sartorius AG, SGS SA, Terumo Corporation, Texcell, Vironova AB and WuXi AppTec.
KEY QUESTIONS ANSWERED IN THIS REPORT
1. How big is the viral inactivation market?
2. What is the future outlook of viral inactivation market?
3. What are the key factors driving the viral inactivation market?
4. Which are the leading companies in the global viral inactivation market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Viral Inactivation Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Product
- 6.1 Reagents and Kits
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Systems
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Services
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
7 Market Breakup by Application
- 7.1 Vaccines and Therapeutics
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Stem Cell Products
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Blood and Blood Products
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Tissue and Tissue Products
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Cellular and Gene Therapy
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
8 Market Breakup by End Use
- 8.1 Pharmaceutical and Biotechnology Companies
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 CROs
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Academic and Research Institutes
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.1.1 United States
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.2.1 China
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.3.1 Germany
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.4.1 Brazil
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Charles River Laboratories
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 Merck KGaA
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 Financials
- 14.3.2.4 SWOT Analysis
- 14.3.3 Parker Hannifin Corp
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.3.4 SWOT Analysis
- 14.3.4 Rad Source Technologies
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 SWOT Analysis
- 14.3.5 Sartorius AG
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.5.4 SWOT Analysis
- 14.3.6 SGS SA
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.7 Terumo Corporation
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 Financials
- 14.3.7.4 SWOT Analysis
- 14.3.8 Texcell
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.9 Vironova AB
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.10 WuXi AppTec
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.10.3 Financials
- 14.3.1 Charles River Laboratories
